Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03247712 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer
A Phase 1 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Providence Health & Services.
- Active
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT03247712: Active Phase 1 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by Providence Health & Services.
NCT03247712 is a Phase 1 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by Providence Health & Services. The registered enrollment target is 22 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03247712, a Phase 1 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Providence Health & Services.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the safety of neoadjuvant immunoradiotherapy as a safe means of down-staging Head and Neck Squamous Cell Carcinoma (HNSCC) prior to surgical resection.
Primary Outcome
Safety endpoint: Number of patients with an Unplanned Delay to Surgery defined as any change to scheduled surgery date considered to be at least possibly related to neoadjuvant treatment.
Conditions Studied
Interventions
- PROCEDURE Surgical Resection
- DRUG Nivolumab
- RADIATION Radiation (5 days)
- RADIATION Radiation (3 days)
Study Locations (1)
Oregon
- Providence Portland Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-01-15 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT03247712 still lists
NCT03247712 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 4 interventions - of which Surgical Resection is the first listed.
NCT03247712 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03247712 about?
NCT03247712 is a clinical study titled "Neoadjuvant Immunoradiotherapy in Head & Neck Cancer". The purpose of this study is to test the safety of neoadjuvant immunoradiotherapy as a safe means of down-staging Head and Neck Squamous Cell Carcinoma (HNSCC) prior to surgical resection.
What is the current status of trial NCT03247712?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2018-01-15. Estimated completion is 2026-12.
What conditions does trial NCT03247712 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT03247712?
The interventions under investigation include: Surgical Resection (PROCEDURE), Nivolumab (DRUG), Radiation (5 days) (RADIATION), Radiation (3 days) (RADIATION).
Who is sponsoring clinical trial NCT03247712?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03247712 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03247712's enrollment target sits among peer trials
22 214th of 250 higher than 33 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
RECRUITING · Phase 1
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI